Total Payments
$1.1M
2024 Payments
$120,297
Companies
49
Transactions
777
Medicare Patients
1,802
Medicare Billing
$585,507
Payment Breakdown by Category
Consulting$640,029 (59.5%)
Research$272,904 (25.4%)
Other$85,176 (7.9%)
Travel$66,828 (6.2%)
Food & Beverage$10,376 (1.0%)
Education$7.68 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $640,029 | 182 | 59.5% |
| Unspecified | $272,904 | 20 | 25.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $83,176 | 40 | 7.7% |
| Travel and Lodging | $66,828 | 87 | 6.2% |
| Food and Beverage | $10,376 | 446 | 1.0% |
| Grant | $2,000 | 1 | 0.2% |
| Education | $7.68 | 1 | 0.0% |
Payments by Type
General
$802,417
757 transactions
Research
$272,904
20 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $331,397 | 357 | $0 (2024) |
| AstraZeneca UK Limited | $283,171 | 37 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $265,377 | 97 | $0 (2024) |
| GENZYME CORPORATION | $58,388 | 51 | $0 (2024) |
| AMAG Pharmaceuticals, Inc. | $35,600 | 1 | $0 (2017) |
| Regeneron Healthcare Solutions, Inc. | $24,448 | 29 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $24,082 | 25 | $0 (2024) |
| SANOFI US SERVICES INC. | $14,643 | 9 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $9,796 | 23 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $7,189 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $120,297 | 134 | GlaxoSmithKline, LLC. ($77,790) |
| 2023 | $185,924 | 139 | GlaxoSmithKline, LLC. ($85,391) |
| 2022 | $98,695 | 101 | AstraZeneca Pharmaceuticals LP ($33,161) |
| 2021 | $135,337 | 82 | AstraZeneca Pharmaceuticals LP ($53,435) |
| 2020 | $160,772 | 53 | AstraZeneca Pharmaceuticals LP ($123,564) |
| 2019 | $45,823 | 114 | GlaxoSmithKline, LLC. ($29,727) |
| 2018 | $47,348 | 88 | GlaxoSmithKline, LLC. ($34,861) |
| 2017 | $281,125 | 66 | AstraZeneca UK Limited ($218,867) |
All Payment Transactions
777 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $6,050.00 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $458.47 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $262.20 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | Cash or cash equivalent | $246.48 | General |
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $171.46 | General |
| 12/12/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: RESPIRATORY | ||||||
| 12/11/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $105.92 | General |
| 12/11/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | Cash or cash equivalent | $43.56 | General |
| 12/11/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $7.86 | General |
| Category: RESPIRATORY | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Consulting Fee | Cash or cash equivalent | $175.00 | General |
| Category: Respiratory | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $13.62 | General |
| Category: RESPIRATORY | ||||||
| 11/21/2024 | Genentech USA, Inc. | Xolair (Biological) | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: Immunology | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $12.47 | General |
| Category: RESPIRATORY | ||||||
| 11/15/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: RESPIRATORY | ||||||
| 11/14/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $9.21 | General |
| Category: RESPIRATORY | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $759.44 | General |
| 11/08/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $247.54 | General |
| 11/08/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | Cash or cash equivalent | $8.71 | General |
| 11/06/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,600.00 | General |
| 11/05/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: RESPIRATORY | ||||||
| 10/31/2024 | Regeneron Healthcare Solutions, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,796.00 | General |
| 10/31/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $8.30 | General |
| Category: RESPIRATORY | ||||||
| 10/28/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,800.00 | General |
| Category: Immunology | ||||||
| 10/24/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $15.55 | General |
| Category: IMMUNOLOGY | ||||||
| 10/22/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $6.00 | General |
| Category: RESPIRATORY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| STRATOS 1 Tralokinumab in Asthma Ph 3 Pivotal Study 1, A 52-Week, Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting B2 Agonist | AstraZeneca UK Limited | $198,611 | 2 |
| A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, SAFETY STUDY OF FERUMOXYTOL COMPARED TO FERRIC CARBOXYMALTOSE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IDA FIRM | AMAG Pharmaceuticals, Inc. | $35,600 | 1 |
| STRATOS 2 Tralokinumab in Asthma Ph 3 Pivotal Study 2, A 52-Week, Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting B2 Agonist | AstraZeneca UK Limited | $20,256 | 2 |
| A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma | AstraZeneca Pharmaceuticals LP | $9,911 | 4 |
| A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Immunomodulatory Effect of the RIPK1 Inhibitor SAR443122 in Hospitalized Patients With Severe COVID-19 | SANOFI US SERVICES INC. | $3,672 | 2 |
| Expert consensus on SABA use for asthma clinical decision-making: a Delphi approach | Teva Pharmaceuticals USA, Inc. | $1,524 | 4 |
| Study to evaluate the efficacy and safety of Tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma | AstraZeneca Pharmaceuticals LP | $1,462 | 2 |
| US expert consensus on short-acting beta-agonist reliever medication use for asthma clinical decision-making: a mixed-method Delphi adjudication approach | Teva Pharmaceuticals USA, Inc. | $1,306 | 1 |
| US Expert Consensus On Short-acting Beta Agonist (SABA) Reliever Medication Use For Asthma Clinical Decision-making: A Mixed-method Delphi Adjudication Approach | Teva Pharmaceuticals USA, Inc. | $288.50 | 1 |
| Clinical Burden and Unmet Need for Severe Asthma and New Users of Biologics | Amgen Inc. | $273.74 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 503 | 4,512 | $415,720 | $171,932 |
| 2022 | 7 | 413 | 4,293 | $272,685 | $101,657 |
| 2021 | 8 | 465 | 2,105 | $302,154 | $117,496 |
| 2020 | 10 | 421 | 4,194 | $399,954 | $194,421 |
Total Patients
1,802
Total Services
15,104
Medicare Billing
$585,507
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0517 | Injection, benralizumab, 1 mg | Office | 2023 | 12 | 780 | $145,381 | $79,434 | 54.6% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2023 | 11 | 2,190 | $72,093 | $40,613 | 56.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 114 | 198 | $71,874 | $20,736 | 28.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 105 | 105 | $57,855 | $14,256 | 24.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 96 | 151 | $37,297 | $10,908 | 29.2% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 54 | 851 | $16,169 | $2,968 | 18.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 27 | 92 | $6,624 | $1,071 | 16.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 13 | 13 | $4,732 | $1,068 | 22.6% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 71 | 132 | $3,696 | $878.84 | 23.8% |
| J2357 | Injection, omalizumab, 5 mg | Office | 2022 | 11 | 3,135 | $101,340 | $57,603 | 56.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 101 | 168 | $60,984 | $16,967 | 27.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 93 | 93 | $51,243 | $11,863 | 23.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 96 | 156 | $38,532 | $11,306 | 29.3% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 38 | 546 | $10,374 | $2,014 | 19.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 22 | 108 | $7,776 | $1,339 | 17.2% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 52 | 87 | $2,436 | $566.38 | 23.3% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2021 | 11 | 600 | $113,220 | $69,458 | 61.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 126 | 126 | $69,426 | $17,195 | 24.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 82 | 132 | $47,916 | $13,586 | 28.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 102 | 159 | $39,273 | $10,938 | 27.9% |
| 95004 | Injection of allergenic extracts into skin, accessed through the skin | Office | 2021 | 53 | 933 | $17,727 | $3,494 | 19.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 22 | 22 | $8,008 | $1,586 | 19.8% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 23 | 65 | $4,680 | $789.34 | 16.9% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2021 | 46 | 68 | $1,904 | $450.12 | 23.6% |
| J0517 | Injection, benralizumab, 1 mg | Office | 2020 | 12 | 780 | $138,600 | $89,518 | 64.6% |
About Dr. John Oppenheimer, MD
Dr. John Oppenheimer, MD is a Allergy healthcare provider based in Cedar Knolls, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1639170871.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Oppenheimer, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $120,297 received in 2024. These payments were reported across 777 transactions from 49 companies. The most common payment nature is "Consulting Fee" ($640,029).
As a Medicare-enrolled provider, Oppenheimer has provided services to 1,802 Medicare beneficiaries, totaling 15,104 services with total Medicare billing of $585,507. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy
- Location Cedar Knolls, NJ
- Active Since 08/10/2005
- Last Updated 05/16/2016
- Taxonomy Code 207KA0200X
- Entity Type Individual
- NPI Number 1639170871
Products in Payments
- TEZSPIRE (Biological) $74,063
- BREZTRI (Drug) $40,834
- NUCALA (Biological) $40,304
- FERAHEME (Drug) $35,600
- TRELEGY ELLIPTA (Drug) $31,586
- DUPIXENT (Biological) $18,075
- DUPIXENT (Drug) $14,715
- STIOLTO RESPIMAT (Drug) $9,719
- ProAir Digihaler (Drug) $8,476
- Auvi-Q (Drug) $2,887
- SHINGRIX (Biological) $2,815
- AirDuo Digihaler (Drug) $2,105
- NO PRODUCT DISCUSSED (Drug) $1,908
- FASENRA (Drug) $1,866
- Xhance (Drug) $1,645
- AUVI-Q (Drug) $1,107
- SKYRIZI (Biological) $1,050
- ArmonAir Digihaler (Drug) $1,019
- PROAIR RESPICLICK (Drug) $850.71
- Xolair (Biological) $247.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.